The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease
Open accessAbstract
A proposed key event in the pathogenesis of Alzheimer's disease (AD) is the formation of neurotoxic amyloid beta (Abeta) oligomers and amyloid plaques in specific brain regions that are affected by the disease. The main plaque component is the 42 amino acid isoform of Alphabeta (Abeta1-42), which is thought to initiate plaque formation and AD pathogenesis. Numerous isoforms of Abeta, e.g., Abeta1-42, Abeta1-40 and the 3-pyroglutamate derivate of Abeta3-42 (pGluAbeta3-42), have been detected in the brains of sporadic AD (SAD) and familial AD (FAD) subjects. However, the relative importance of these isoforms in the pathogenesis of AD is not fully understood. Here, we report a detailed study using immunoprecipitation in combination with mass spectrometric analysis to determine the Abeta isoform pattern in the cerebellum, cortex and hippocampus in AD, including subjects with a mutation in the presenilin (M146V) or amyloid precursor protein (KM670/671NL) genes, SAD subjects and non-demented controls. We show that the dominating Abeta isoforms in the three different brain regions analyzed from control, SAD, and FAD are Abeta1-42, pGluAbeta3-42, Abeta4-42 and Abeta1-40 of which Abeta1-42 and Abeta4-42 are the dominant isoforms in the hippocampus and the cortex in all groups analyzed, controls included. No prominent differences in Abeta isoform patterns between FAD and SAD patients were seen, underscoring the similarity in the amyloid pathology of these two disease entities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Among the different Aβ variants, the N-terminally truncated peptide Aβ4–42 is among the most abundant.”
From Characterization of a Mouse Model of Alzheimer’s Disease Expressing Aβ4-42 and Human Mutant Tau (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 1×
“b-Secretase is an aspartyl protease encoded by the b-site APP-cleaving enzyme 1 (BACE1) gene [18, 34, 37, 39] while c-secretase is a protease complex consisting of at least four essential components of which the homologous presenilin 1 and 2 proteins (PSEN1 and PSEN2, respectively) constitute the active site [5].”
BackgroundPhases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Purification and cloning of amyloid precursor protein β-secretase from human brain
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., et al. (1999) · Nature · doi:10.1038/990114 · Cited by 1,612
Cited by
Sorted by citations
Items 301–348 of 348
Cerebrospinal fluid biomarkers for differentiating between Alzheimer’s disease and Vascular dementia
Bjerke, M. (2011) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Amyloid-β Protofibrils in Alzheimer´s Disease : Focus on Antibodies, Inflammation and Astrocytes
Söllvander, S. (2015) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Fluid Biomarkers and Diagnostics
Zetterberg, H., & Blennow, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00021-6
Self-citationKurdakova, A. (2016) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5882
In Vitro and In Vivo Studies on Antibodies - N-terminally Truncated Abeta in the 5XFAD Mouse Model
Richard, B. C. (2015) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5098
Borgers, H. (2017) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6363
The postsynaptic protein neurogranin: a new item in the Alzheimer’s disease biomarker toolbox
Kvartsberg, H. (2019) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Studie zur Rolle N-trunkierter Amyloid-β-Peptide bei der Alzheimer-Krankheit
Gießen, N. M.-E. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7657
Strain-specific profiling of Amyloid-β in Alzheimer´s disease: functional and clinical signature
Noor, A. (2020) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7997
Current literature in mass spectrometry
John Wiley & Sons, L. (2010) · Journal of Mass Spectrometry · doi:10.1002/jms.1665
The role of N-truncated Aβ peptides in Alzheimer’s Disease
López‐Noguerola, J. S. (2018) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6949
Zampar, S. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9004
Quantitative Analysen hippocampaler Interneuronen in zwei transgenen Alzheimer Mausmodellen
Giesers, N. K. (2022) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9447
WIN-55,212-2-Therapie in einem Modell für die sporadische Alzheimer Erkrankung
Ott, F. W. (2022) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9572
Henniges, P. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9694
Horkulak, N. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-10060
Sasmita, A. O. (2024) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-10403
Curdt, N. (2024) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-10405
Caffeine and potential use in Alzheimer’s disease
Büschgens, L., Janitschke, D., Lauer, A. A., Grimm, M. O. W., & Wirths, O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13868-3.00029-6
γ-Secretase in the pathogenesis of Alzheimer’s disease and therapeutic potential of its modulators
Николаевич, В. В., Иванович, В. В., & Shabanov, P. D. (2024) · Психофармакология и биологическая наркология · doi:10.17816/phbn635851
Koutarapu, S., Roberts, K. F., Coyle, R. A., Mehla, J., Sato, C., Zipfel, G. J., Bateman, R. J., Schwetye, K. E., & Mukherjee, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.11.658821
Factors Driving Amyloid Beta Fibril Recognition by Cell Surface Receptors: A Computational Study
Slater, O., & Kontoyianni, M. (2025) · Molecules · doi:10.3390/molecules30204116 · Cited by 1
Molecular chaperone and chaperone-based therapeutic approaches for Alzheimer’s disease
Anand, T., & Kumar, A. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.11.006
Dietrich, K. (2015) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4863
Joshi, P., Riffel, F., Kumar, S., Villacampa, N., Theil, S., Parhizkar, S., Haass, C., Colonna, M., Heneka, M. T., Arzberger, T., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16829558
Joshi, P., Riffel, F., Kumar, S., Villacampa, N., Theil, S., Parhizkar, S., Haass, C., Colonna, M., Heneka, M. T., Arzberger, T., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16829555
Therapeutic potential of honey in Alzheimer’s disease management
Sharma, S., Sharma, J., & Maharana, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34147-2.00021-8
del Valle, M. L., & Arienzo, D. (2026) · Ibrain · doi:10.1002/ibra.70016
Molecular mechanisms of action of MT-MMPs involved in the pathogenesis of Alzheimer’s disease
García‐González, L. (2020) · theses.fr (ABES) · doi:10.70675/a04672c0z1f4az472ezbcd5zbea446eac50c
Effects of zinc and copper ions in the amyloid cascade linked to Alzheimer's disease
Borghesani, V. (2018) · theses.fr (ABES) · doi:10.70675/d82c3f9az0deaz45e9z9097zeb1f4fd0a45b
Valverde, A. (2020) · theses.fr (ABES) · doi:10.70675/f1b70734zf4e3z4870z8fbdz950d831642a7
Bouakil, M. (2020) · theses.fr (ABES) · doi:10.70675/acd6af1dz6ff0z4966z9e5dzb1021e13dae0
Various Immunotherapy and Targeted Therapeutics for Managing Alzheimer’s Disease
Verma, M., & Singh, N. K. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814953126010010
Zampar, S., Fricke, M., Kremser, F., Talucci, I., Maric, H. M., Klafki, H., Rostagno, A. A., Jahn, O., Weggen, S., Ghiso, J. A., et al. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05912-x
Szczerba, P., Stefaniak, E., Płonka, D., Wezynfeld, N. E., & Bal, W. (2026) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2026.113387 · Cited by 1
Elmkvist, S. B., Thygesen, C., Jensen, P., Pihl, M., Freude, K., Finsen, B. R., & Larsen, M. R. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c01160
Biernat, K., Wezynfeld, N., Wróblewski, W., Ciosek-Skibińska, P., & Tobolska, A. (2026) · Talanta: The International Journal of Pure and Applied Analytical Chemistry · doi:10.1016/j.talanta.2026.130647
Murine Aβ4–x Peptides Retain High-Affinity Redox-Silent Cu2+ Binding
Drew, S. C. (2026) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.6c04247
Abd-Elraouf, K., Murphy, D. T., Cheong, L. Y. T., Zeng, J., & Lo, C. H. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00591-z
Metadata
- Authors
- Portelius, E., Bogdanovic, N., Gustavsson, M. K., Volkmann, I., Brinkmalm, G., Zetterberg, H., Winblad, B., & Blennow, K.
- Affiliations
- University of Gothenburg (SE)
- Karolinska Institutet (SE)
- Corresponding author
- Portelius, Erik
- Venue
- Acta Neuropathologica
- Published
- 2010-04-24
- Volume
- 120
- Issue
- 2
- Pages
- 185-193
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC3568930
- OpenAlex
- W2045197448
- Cited by
- 348
- References
- 41
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 27 · 2023: 22 · 2022: 21 · 2021: 25 · 2020: 26 · 2019: 28 · 2018: 26 · 2017: 20 · 2016: 22 · 2015: 31 · 2014: 23 · 2013: 10 · 2012: 16
- FWCI
- 9.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Neuropathologica (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Institute on Aging (K08 AG-22228, AG023185, K08AG022228, U01AG016976, P50AG005131, AG-O5131, R01AG023185)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta isoforms, amyloid-beta 42, Aβ40, amyloid-beta oligomers, amyloid plaques, familial Alzheimer's disease, sporadic Alzheimer's disease, amyloid precursor protein mutations, hippocampus, cerebral cortex, cerebellum
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Male, Middle Aged, Peptide Fragments, Mass Spectrometry, Statistics as Topic, Amyloid beta-Peptides, Protein Isoforms, Immunoprecipitation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
